Get the Stockscreener App
45.36
0.37%
-0.17
Royalty Pharma Plc stock is traded at $45.36, with a volume of 8.39M.
It is down -0.37% in the last 24 hours and up +0.53% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$45.53
Open:
$45.77
24h Volume:
8.39M
Relative Volume:
2.31
Market Cap:
$19.43B
Revenue:
$2.38B
Net Income/Loss:
$1.32B
P/E Ratio:
25.47
EPS:
1.7806
Net Cash Flow:
$897.24M
1W Performance:
-0.64%
1M Performance:
+0.53%
6M Performance:
+25.17%
1Y Performance:
+35.40%
1-Day Range:
$44.73
$46.10
1-Week Range:
$44.73
$46.44
52-Week Range:
$29.66
$47.86
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.36 | 19.43B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
(RPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
FOMO Trade: Will Royalty Pharma plc benefit from rate cuts2026 Setups & AI Optimized Trade Strategies - baoquankhu1.vn
Royalty Pharma PLC $RPRX Shares Purchased by Tudor Investment Corp ET AL - MarketBeat
S&P 500 Futures Decline In Premarket Trading; Super Micro Computer, Royalty Pharma Lag - 富途牛牛
S&P 500 Futures Decline in Premarket Trading; Super Micro Computer, Royalty Pharma Lag - Barron's
Aug Action: Does Royalty Pharma plc have high return on assets2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Does Royalty Pharma plc have high return on assets2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Royalty Pharma PLC $RPRX Stock Position Raised by JPMorgan Chase & Co. - MarketBeat
Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M - MSN
RPRX: Entities report multi‑date sell notices including 136,980‑share trade - Stock Titan
Royalty Pharma plc (RPRX) earns $51 target as 2026 growth outlook exceeds expectations - MSN
[144] Royalty Pharma plc SEC Filing - Stock Titan
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma - MSN
54,266 Shares in Royalty Pharma PLC $RPRX Acquired by WBI Investments LLC - MarketBeat
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout - ChartMill
Royalty Pharma names Greg Butz as EVP of partnering, investments By Investing.com - Investing.com South Africa
Royalty Pharma plc (RPRXN.MX) Stock Price, News, Quote & History - Yahoo Finance
Royalty Pharma Announces Expansion of Leadership Team - The Manila Times
Royalty Pharma hires Bank of America healthcare banking executive - StreetInsider
Royalty Pharma PLC $RPRX Shares Bought by L2 Asset Management LLC - MarketBeat
Royalty Pharma Plc Experiences Valuation Adjustment Amid Strong Market Performance Metrics - Markets Mojo
Dorsey Asset Management LLC Buys Shares of 2,350,449 Royalty Pharma PLC $RPRX - MarketBeat
Clark Capital Management Group Inc. Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
182,068 Shares in Royalty Pharma PLC $RPRX Acquired by Braidwell LP - MarketBeat
Swiss National Bank Sells 22,000 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma : TD Cowen Conference Transcript - marketscreener.com
Royalty Pharma Plc Experiences Valuation Adjustment Amidst Competitive Market Dynamics - Markets Mojo
Royalty Pharma PLC $RPRX Shares Bought by Korea Investment CORP - MarketBeat
A Look At Royalty Pharma (RPRX) Valuation After New Asia Expansion Leadership Appointment - Sahm
Magnetar Financial LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Russell Investments Group Ltd. Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
The Bull Case For Royalty Pharma (RPRX) Could Change Following Asia Leadership Hire To Target Biotech Royalties - simplywall.st
WINTON GROUP Ltd Takes $3.36 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Capital International Investors Raises Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by Capital International Sarl - MarketBeat
Price-Driven Insight from (RPRX) for Rule-Based Strategy - Stock Traders Daily
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 10th Largest Position - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Decreased by Rhenman & Partners Asset Management AB - MarketBeat
Neo Ivy Capital Management Buys New Position in Royalty Pharma PLC $RPRX - MarketBeat
Goodman Advisory Group LLC Purchases New Stake in Royalty Pharma PLC $RPRX - MarketBeat
CM Management LLC Takes $1.76 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN
Royalty Pharma Plc Hits New 52-Week High of USD 47.86 - Markets Mojo
Vera Therapeutics Appoints Christopher Hite to Board of Directors - GlobeNewswire Inc.
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.66 - Markets Mojo
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - MarketBeat
Insider sales of common stock — Repare Therapeutics (NASDAQ: RPRX) - Stock Titan
Victory Capital Management Inc. Purchases 165,727 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):